Skip to main content

Health Care Policy Press


SNO CLINICAL TRIALS COURSE
November 17-18, 2020


SNO Clinical Trials Course

The Society for Neuro-Oncology is pleased to host a 2-day Virtual Clinical Trials Course, Tuesday and Wednesday, November 17 – 18, 2020 from 9am - 1pm (US Central Time) both days. After the overwhelmingly positive feedback from the first course in 2019, the planning committee has expanded the course both to the number of participants as well as the content. A series of didactic lectures will be presented by pre-eminent faculty with specific areas of expertise with respect to clinical trial design and conduct and will be open to all interested colleagues. These presentations will also be recorded and available for viewing at the conclusion of the course on the SNO website. Click here to view the preliminary program.  

Registration
There is no fee for this year's course, however, all who wish to view the didactic content must register to do so. Note that each day has its own registration linkPlease make sure to register for both days.
Day 1: Click here to register   
Day 2: Click here to register   

Scholars Forum
In addition to the didactic portion of the course, a cohort of 36 scholars has been selected from applications received, who will provide a more detailed protocol synopsis that will be shared with faculty mentors and statisticians. This group will have the opportunity to receive feedback both before the actual course and at two small group closed sessions for in-depth discussion with the mentors. These small group sessions will be held after the didactic portion on each day of the conference, from 1:30pm - 3:30pm.

Educational Goals

Upon completion of this course, participants will have an improved understanding of the practical aspects of therapeutic CNS trials, including: understanding the fundamentals of good trial design; understanding the scientific, statistical, regulatory, logistical and ethical aspects of CNS trials; integrating correlative studies in CNS trials; mitigating challenges to accrual and overcoming accrual barriers; and anticipating the future direction of CNS trials.


Planning Committee
  • Stephen Bagley, MD, University of Pennsylvania
  • Susan Chang, MD, University of California, San Francisco
  • Maryam Fouladi, MD, Cincinnati Children's Hospital
  • Mustafa Khasraw, MBChB, MD, Duke University
  • Annette Molinaro, PhD, University of California, San Francisco
  • Ian Parney, MD, PhD, Mayo Clinic
  • Vinay Puduvalli, MD, MD Anderson Cancer Center
  • Erik Sulman, MD, PhD, NYU Langone Medical Center
  • Patrick Wen, MD, Dana-Farber Cancer Institute